0001510964-20-000064.txt : 20200806 0001510964-20-000064.hdr.sgml : 20200806 20200806160738 ACCESSION NUMBER: 0001510964-20-000064 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200806 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200806 DATE AS OF CHANGE: 20200806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CV Sciences, Inc. CENTRAL INDEX KEY: 0001510964 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 800944970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-54677 FILM NUMBER: 201081622 BUSINESS ADDRESS: STREET 1: 10070 BARNES CANYON ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 866-290-2157 MAIL ADDRESS: STREET 1: 10070 BARNES CANYON ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: CannaVEST Corp. DATE OF NAME CHANGE: 20130205 FORMER COMPANY: FORMER CONFORMED NAME: Foreclosure Solutions, Inc. DATE OF NAME CHANGE: 20110124 8-K 1 cvsi8k08062020.htm 8-K Document
false0001510964 0001510964 2020-08-06 2020-08-06


 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 6, 2020

CV SCIENCES, INC.
(Exact name of registrant as specified in its charter)

Delaware
000-54677
80-0944970
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

10070 Barnes Canyon Road
San Diego, California 92121
(Address of principal executive offices)

(866) 290-2157
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of exchange on which registered
N/A
 
 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

1


Item 2.02    Results of Operations and Financial Conditions

The information provided below in "Item 7.01 - Regulation FD Disclosure" of this Current Report on Form 8-K is incorporated by reference into this Item 2.02.

Item 7.01    Regulation FD Disclosure 

On August 6, 2020, CV Sciences, Inc. (the "Company") issued a press release regarding the Company’s financial results for its fiscal quarter ended June 30, 2020. A copy of that press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.The press release includes non-GAAP financial measures as defined in Regulation G. The press release also includes a presentation of the most directly comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the United States (GAAP), information reconciling the non-GAAP financial measures to the GAAP financial measures and a discussion of the reasons why the Company’s management believes that presentation of the non-GAAP financial measures provides useful information to investors regarding the Company’s financial condition and results of operations. The non-GAAP financial measures presented therein should be considered in addition to, not as a substitute for, or superior to, financial measures calculated and presented in accordance with GAAP.

Exhibit 99.1 contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what is expressed in these forward-looking statements.

The information set forth under Item 7.01 of this Current Report on Form 8-K (“Current Report”), including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

Item 9.01    Financial Statements and Exhibits

(d) Exhibits



2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 6, 2020

 
CV SCIENCES, INC.
 
 
 
 
 
 
 
By: /s/ Joseph Dowling
 
Joseph Dowling
 
Chief Executive Officer


3
 EX-99.1 2 pressrelease08062020.htm EXHIBIT 99.1 Exhibit



Exhibit 99.1


CV Sciences, Inc. Reports Second Quarter 2020 Financial Results

San Diego, CA - August 6, 2020 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended June 30, 2020.

Second Quarter 2020 and Recent Operating Highlights
•
Revenue of $5.4 million for the second quarter of 2020;
•
E-commerce sales of $2.0 million for the second quarter of 2020;
•
Gross margin of 43.0% for the second quarter of 2020;
•
Maintained strong total cash balance of $8.1 million at quarter end;
•
Received formal notice of patent issuance from USPTO for proprietary CBD and nicotine formulation and treatment of smokeless tobacco addiction;
•
Launched CVTM Acute, a clinically researched wide spectrum proprietary plant-based formula which supports immune system and respiratory health;
•
Launched Happy LaneTM, a new THC-free CBD brand and product line for the convenience store channel; and
•
Announced publication of two research studies demonstrating the safety and health benefits of PlusCBDTM products.

“We continue to effectively navigate the challenging industry and COVID-19 environment by controlling costs and accelerating new product and category development, while continuing to drive distribution growth for our PlusCBDTM brand. During the quarter, we expanded distribution of our topical products with a leading southeast supermarket retailer and two national supermarket retailers, driving further growth of our store count to 6,325 stores nationwide, up from 5,799 at the end of the first quarter. We remain highly confident in the long-term outlook for the hemp-derived CBD category and will continue to position ourselves for the future of CBD as the regulatory environment continues to develop,” stated Joseph Dowling, Chief Executive Officer of CV Sciences. “We are excited to expand our high-quality product development expertise into the immunity category with the recent launch of CVTM Acute, our first entry into the immunity category with additional products to follow. The immunity category for dietary supplements is a promising and growing category with strong consumer demand as consumers focus on their health and well-being during this pandemic. We are leveraging our years of product development expertise to deliver a superior solution for




consumers. The product not only broadens our category exposure, but will also expand our distribution footprint. Additionally, earlier this week we announced the launch of our new Happy LaneTM product line, expanding our hemp-derived CBD portfolio that significantly broadens our channel opportunities, providing an attractive entry point to consumers. With these new and further planned product and brand launches, we see significant opportunity to broaden our national footprint and expand our market share in the CBD category. Beyond these recent new product and brand innovations, we continue to have a pipeline of new product innovation lined up for the 2nd half of 2020. We will continue to focus on expanding our distribution, products, categories and opportunity with a focus on driving growth and long-term shareholder value.”

Operating Results - Second Quarter 2020 Compared to Second Quarter 2019
Sales for the second quarter of 2020 were $5.4 million, a decrease of 68% from $16.9 million in the second quarter of 2019. Second quarter sales were impacted by the current COVID-19 pandemic and increased market competition, which is largely due to the uncertain regulatory environment for CBD. The Company's retail store count increased to 6,325 stores nationwide as of June 30, 2020, up from 4,591 stores as of June 30, 2019.

The Company recognized an operating loss of $4.7 million in the second quarter of 2020, compared to an operating income of $1.3 million in the prior year.

The Company had negative adjusted EBITDA for the second quarter of 2020 of $3.2 million, compared to adjusted EBITDA of$3.6 million for the second quarter of 2019.

Conference Call and Webcast
The Company will host a conference call and webcast to discuss these results today at 4:30 pm EDT/1:30 pm PDT. The webcast of the conference call will be available on the Investor Relations section of the Company's web site at https://ir.cvsciences.com/news-events or directly http://public.viavid.com/index.php?id=140785. Investors interested in participating in the live call can also dial (888) 317-6003, passcode: 6531425 from the U.S. or international callers can dial (412) 317-6061, passcode: 6531425. A telephone replay will be available approximately two hours after the call concludes, and will be available through Thursday, August 13, 2020, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 10146370.







About CV Sciences, Inc.

CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based dietary supplements and CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics. The Company’s PlusCBD™ products are sold at more than 6,300 retail locations throughout the U.S. and it is the top-selling brand of hemp-derived CBD in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry.  CV Sciences follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s products are processed, produced, and tested throughout the manufacturing process to confirm strict compliance with company standards and specifications.  With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov.  PlusCBD™ was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California.  Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

Forward Looking Statements
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risk and uncertainties.

Contact Information

Investor Contact:
ICR
Scott Van Winkle
617-956-6736
scott.vanwinkle@icrinc.com

Media Contact:
ICR
Cory Ziskind
646-277-1232
cory.ziskind@icrinc.com







CV SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(in thousands, except per share data)
 
Three Months ended
June 30,
 
Six Months ended
June 30,
 
2020
 
2019
 
2020
 
2019
Product sales, net
$
5,396

 
$
16,854

 
$
13,666

 
$
31,765

Cost of goods sold
3,074
 
4,903
 
7,336
 
9,255
Gross Profit
2,322
 
11,951
 
6,330
 
22,510
 
 
 
 
 
 
 
 
Operating expenses:
 
 
 
 
 
 
 
Research and development
746

 
1,688

 
2,255

 
3,030

Selling, general and administrative
6,233
 
9,009
 
14,052
 
27,604
 
6,979
 
10,697
 
16,307
 
30,634
 
 
 
 
 
 
 
 
Operating Income (Loss)
(4,657
)
 
1,254

 
(9,977
)
 
(8,124
)
 
 
 
 
 
 
 
 
Interest (income) expense, net
4

 
(1
)
 
(6
)
 
5
Income (loss) before income taxes
(4,661
)
 
1,255

 
(9,971
)
 
(8,129
)
Income tax expense (benefit)
20

 
26

 
(138
)
 
26

Net Income (Loss)
$
(4,681
)
 
$
1,229

 
$
(9,833
)
 
$
(8,155
)
 
 
 
 
 
 
 
 
Weighted average common shares outstanding
 
 
 
 
 
 
 
Basic
99,863

 
98,633

 
99,771

 
98,557

Diluted
99,863

 
120,929

 
99,771

 
98,557

Net loss per common share, basic and diluted


 


 


 


Basic
$
(0.05
)
 
$
0.01

 
$
(0.10
)
 
$
(0.08
)
Diluted
$
(0.05
)
 
$
0.01

 
$
(0.10
)
 
$
(0.08
)








CV SCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(in thousands, except per share data)

 
June 30,
2020
 
December 31,
2019
Assets
 

 
 

Current assets:
 

 
 

Cash and cash equivalents
$
7,576

 
$
9,107

Restricted cash
501

 
501

Accounts receivable, net
1,145

 
2,177

Inventory
8,418

 
9,971

Prepaid expenses and other
8,809

 
10,611

Total current assets
26,449

 
32,367

 
 
 
 
Property & equipment, net
3,039

 
3,615

Operating lease assets
8,147

 
8,709

Intangibles, net
3,748

 
3,766

Goodwill
2,788

 
2,788

Other assets
1,524

 
1,442

Total assets
$
45,695

 
$
52,687

 
 
 
 
Liabilities and stockholders' equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
743

 
$
1,617

Accrued expenses
10,132

 
10,856

Operating lease liability - current
837

 
723

Total current liabilities
11,712

 
13,196

 
 
 
 
Debt
2,906

 
—

Operating lease liability
8,826

 
9,517

Deferred tax liability
263

 
421

Other liabilities
—

 
406

Total liabilities
23,707

 
23,540

 
 
 
 
Commitments and contingencies
 
 
 
 
 
 
 
Stockholders' equity
 
 
 
Preferred stock, par value $0.0001; 10,000 shares authorized; no shares issued and outstanding
—

 
—

Common stock, par value $0.0001; 190,000 shares authorized, 99,886 and 99,416 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively
10

 
10

Additional paid-in capital
73,448

 
70,774

Accumulated deficit
(51,470
)
 
(41,637
)
Total stockholders' equity
21,988

 
29,147

 
 
 
 
Total liabilities and stockholders' equity
$
45,695

 
$
52,687







CV SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW (UNAUDITED)
(in thousands)
 
Six Months ended June 30,
 
2020
 
2019
OPERATING ACTIVITIES
 
 
 
Net loss
$
(9,833
)
 
$
(8,155
)
Adjustments to reconcile net loss to net cash flows provided by (used in) operating activities:
 
 
 
Depreciation and amortization
389

 
354

Stock-based compensation
2,501

 
4,216

Stock-based compensation associated with founders employment settlement
—

 
7,857

Deferred taxes
(158
)
 
—

Non-cash lease expense
562

 
251

Loss on sale of property and equipment
176

 
—

Other
99

 
32

Change in operating assets and liabilities:
 
 
 
Accounts receivable
1,032

 
(1,380
)
Inventory
1,738

 
(557
)
Prepaid expenses and other
2,208

 
(622
)
Accounts payable and accrued expenses
(2,818
)
 
1,461

Net cash provided by (used in) operating activities
(4,104
)
 
3,457

 
 
 
 
INVESTING ACTIVITIES
 
 
 
Purchase of property and equipment
(506
)
 
(504
)
Net cash flows used in investing activities
(506
)
 
(504
)
 
 
 
 
FINANCING ACTIVITIES
 
 
 
Proceeds from debt
2,906

 
—

Repayment of unsecured debt
—

 
(405
)
Proceeds from exercise of stock options
173

 
254

Net cash flows provided by (used in) financing activities
3,079

 
(151
)
 
 
 
 
Net increase (decrease) in cash, cash equivalents and restricted cash
(1,531
)
 
2,802

Cash, cash equivalents and restricted cash, beginning of period
9,608

 
12,935

Cash, cash equivalents and restricted cash, end of period
$
8,077

 
$
15,737

 
 
 
 
Supplemental cash flow disclosures:
 
 
 
Interest paid
$
—

 
$
9

Income taxes paid
$
18

 
$
54

Supplemental disclosure of non-cash transactions:
 
 
 
Purchase of property and equipment in accounts payable and accrued expenses
$
327

 
$
50

Sale of property and equipment in exchange for note receivable (recorded in prepaid expenses and other) and inventory
$
675

 
$
—









CV SCIENCES, INC.
NON-GAAP FINANCIAL MEASURES (UNAUDITED)

We prepare our condensed consolidated financial statements in accordance with generally accepted accounting principles for the United States (GAAP). The non-GAAP financial measures such as net income and loss per share and Adjusted EBITDA included in this press release are different from those otherwise presented under GAAP. We use non-GAAP measures internally to evaluate our performance and make financial and operational decisions that are presented in a manner that adjusts from their equivalent GAAP measures or that supplement the information provided by our GAAP measures. The non-GAAP financial measures exclude non-cash compensation expense for stock options and other non-recurring items. When evaluating the performance of our business and developing short and long-term plans, we do not consider share-based compensation charges. Although share-based compensation is necessary to attract and retain quality employees, our consideration of share-based compensation places its primary emphasis on overall shareholder dilution rather than the accounting charges associated with such grants. Because of the varying availability of valuation methodologies and subjective assumptions, we believe that the exclusion of share-based compensation allows for more accurate comparison of our financial results to previous periods. In addition, we believe it useful to investors to understand the specific impact of the application of the fair value method of accounting for share-based compensation on our operating results.
Adjusted EBITDA is defined by us as EBITDA (net income (loss) plus depreciation expense, amortization expense, interest and income tax expense (benefit), further adjusted to exclude certain non-cash expenses and other adjustments as set forth below. We use Adjusted EBITDA because we believe it more clearly highlights trends in our business that may not otherwise be apparent when relying solely on GAAP financial measures, since Adjusted EBITDA eliminates from our results specific financial items that have less bearing on our core operating performance.
We use Adjusted EBITDA in communicating certain aspects of our results and performance, including in this press release, and believe that Adjusted EBITDA, when viewed in conjunction with our GAAP results and the accompanying reconciliation, can provide investors with greater transparency and a greater understanding of factors affecting our financial condition and results of operations than GAAP measures alone. In addition, we believe the presentation of Adjusted EBITDA is useful to investors in making period-to-period comparison of results because the adjustments to GAAP are not reflective of our core business performance.




A reconciliation from our GAAP net loss to non-GAAP net income (loss) for the three and six months ended June 30, 2020 and 2019 is detailed below:
 
Three Months ended
June 30,
 
Six Months ended
June 30,
 
2020
 
2019
 
2020
 
2019
 
(in thousands, except per share data)
Net income (loss) - GAAP
$
(4,681
)
 
$
1,229

 
$
(9,833
)
 
$
(8,155
)
Stock-based compensation (1)
1,243

 
2,125

 
2,501

 
4,216

Stock-based compensation associated with founder employment settlement (2)
—

 
—

 
—

 
7,857

Payroll expense associated with founder employment settlement (3)
—

 
—

 
—

 
934

Net income (loss) - non-GAAP
$
(3,438
)
 
$
3,354

 
$
(7,332
)
 
$
4,852

 
 
 
 
 
 
 
 
Diluted EPS - GAAP
$
(0.05
)
 
$
0.01

 
$
(0.10
)
 
$
(0.08
)
Stock-based compensation (1)
0.02

 
0.02

 
0.03

 
0.04

Stock-based compensation associated with founder employment settlement (2)
—

 
—

 
—

 
0.07

Payroll expense associated with founder employment settlement (3)
—

 
—

 
—

 
0.01

Diluted EPS - non-GAAP
$
(0.03
)
 
$
0.03

 
$
(0.07
)
 
$
0.04

 
 
 
 
 
 
 
 
Shares used to calculate diluted EPS - GAAP
99,863

 
120,929

 
99,771

 
98,557

Shares used to calculate diluted EPS - non-GAAP
99,863

 
120,929

 
99,771

 
120,273

_____________
(1)
Represents stock-based compensation expense related to stock options awarded to employees, consultants and non-executive directors based on the grant date fair value using the Black-Scholes valuation model.
(2)
Represents stock-based compensation expense related to accelerated vesting of RSU's and the modification of certain stock options associated with the settlement agreements with our founder.
(3)
Represents accrued payroll and related benefits associated with the separation of our founder.







A reconciliation from our net loss to Adjusted EBITDA, a non-GAAP measure, for the three months ended June 30, 2020 and 2019 is detailed below:
 
Three Months ended June 30, 2020
 
Three Months ended June 30, 2019
 
Consumer Products
 
Specialty Pharma
 
Total
 
Consumer Products
 
Specialty Pharma
 
Total
 
(in thousands)
Net income (loss)
$
(4,034
)
 
$
(647
)
 
$
(4,681
)
 
$
2,248

 
$
(1,019
)
 
$
1,229

Depreciation
195

 
—

 
195

 
168

 
—

 
168

Amortization
—

 
9

 
9

 
—

 
9

 
9

Interest expense (income)
4

 
—

 
4

 
(1
)
 
—

 
(1
)
Income tax expense
20

 
—

 
20

 
26

 
—

 
26

EBITDA
(3,815
)
 
(638
)
 
(4,453
)
 
2,441

 
(1,010
)
 
1,431

Stock-based compensation (1)
1,209

 
34

 
1,243

 
2,090

 
35

 
2,125

Adjusted EBITDA
$
(2,606
)
 
$
(604
)
 
$
(3,210
)
 
$
4,531

 
$
(975
)
 
$
3,556

A reconciliation from our net loss to Adjusted EBITDA, a non-GAAP measure, for the six months ended June 30, 2020 and 2019 is detailed below:
 
Six Months ended June 30, 2020
 
Six Months ended June 30, 2019
 
Consumer Products
 
Specialty Pharma
 
Total
 
Consumer Products
 
Specialty Pharma
 
Total
 
(in thousands)
Net loss
$
(7,973
)
 
$
(1,860
)
 
$
(9,833
)
 
$
(6,483
)
 
$
(1,672
)
 
$
(8,155
)
Depreciation
371

 
—

 
371

 
336

 
—

 
336

Amortization
—

 
18

 
18

 
—

 
18

 
18

Interest expense (income)
(6
)
 
—

 
(6
)
 
5

 
—

 
5

Income tax expense (benefit)
(138
)
 
—

 
(138
)
 
26

 
—

 
26

EBITDA
(7,746
)
 
(1,842
)
 
(9,588
)
 
(6,116
)
 
(1,654
)
 
(7,770
)
Stock-based compensation (1)
2,467

 
34

 
2,501

 
4,137

 
79

 
4,216

Stock-based compensation associated with founder employment settlement (2)
—

 
—

 
—

 
7,857

 
—

 
7,857

Payroll expense associated with founder employment settlement (3)
—

 
—

 
—

 
934

 
—

 
934

Adjusted EBITDA
$
(5,279
)
 
$
(1,808
)
 
$
(7,087
)
 
$
6,812

 
$
(1,575
)
 
$
5,237

______________
(1)
Represents stock-based compensation expense related to stock options awarded to employees, consultants and non-executive directors based on the grant date fair value using the Black-Scholes valuation model.
(2)
Represents stock-based compensation expense related to accelerated vesting of RSU's and the modification of certain stock options associated with the settlement agreements with our founder.
(3)
Represents accrued payroll and related benefits associated with the separation of our founder.






EX-101.SCH 3 cvsi-20200630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0004000 - Document - Cover Document link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 cvsi-20200630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 cvsi-20200630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 cvsi-20200630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 7 cvsi-20200630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 cvsi8k08062020_htm.xml IDEA: XBRL DOCUMENT 0001510964 2020-08-06 2020-08-06 false 0001510964 8-K 2020-08-06 CV SCIENCES, INC. DE 000-54677 80-0944970 10070 Barnes Canyon Road San Diego CA 92121 866 290-2157 false false false false false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover Document
Aug. 06, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 06, 2020
Entity Registrant Name CV SCIENCES, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 000-54677
Entity Tax Identification Number 80-0944970
Entity Address, Address Line One 10070 Barnes Canyon Road
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 866
Local Phone Number 290-2157
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001510964
Amendment Flag false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 0004000 - Document - Cover Document Sheet http://cvsciences.com/role/CoverDocument Cover Document Cover 1 false false All Reports Book All Reports cvsi8k08062020.htm cvsi-20200630.xsd cvsi-20200630_cal.xml cvsi-20200630_def.xml cvsi-20200630_lab.xml cvsi-20200630_pre.xml pressrelease08062020.htm http://xbrl.sec.gov/dei/2020-01-31 true true JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cvsi8k08062020.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "cvsi-20200630_cal.xml" ] }, "definitionLink": { "local": [ "cvsi-20200630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "cvsi8k08062020.htm" ] }, "labelLink": { "local": [ "cvsi-20200630_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "cvsi-20200630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "cvsi-20200630.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 20, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cvsi", "nsuri": "http://cvsciences.com/20200630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "cvsi8k08062020.htm", "contextRef": "D2020Q3Aug6", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0004000 - Document - Cover Document", "role": "http://cvsciences.com/role/CoverDocument", "shortName": "Cover Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "cvsi8k08062020.htm", "contextRef": "D2020Q3Aug6", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvsciences.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvsciences.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvsciences.com/role/CoverDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvsciences.com/role/CoverDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvsciences.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvsciences.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvsciences.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvsciences.com/role/CoverDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvsciences.com/role/CoverDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvsciences.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvsciences.com/role/CoverDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvsciences.com/role/CoverDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvsciences.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvsciences.com/role/CoverDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvsciences.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvsciences.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvsciences.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvsciences.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://cvsciences.com/role/CoverDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r3": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r4": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001510964-20-000064-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001510964-20-000064-xbrl.zip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